QI
RAPT

QS Investors’s RAPT Therapeutics RAPT Stock Holding History

QS Investors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$404K Sell
1,588
-462
-23% -$86.3K ﹤0.01% 826
2021
Q1 		$365K Hold
2,050
– – ﹤0.01% 910
2020
Q4 		$324K Buy
+2,050
New +$446K ﹤0.01% 958

Other funds holding RAPT

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return

QS Investors's RAPT Position: Q2 2021 in Review

QS Investors reduced its RAPT Therapeutics (RAPT) stake by 23% in Q2 2021, selling an estimated $86.3K and leaving 1,588 shares worth $404K. The position accounts for ﹤0.01% of the portfolio, ranked #826.

QS Investors first reported a position in RAPT in Q4 2020 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold RAPT as of Q2 2021.

  • QS Investors held 1,588 shares of RAPT Therapeutics worth $404K as of Q2 2021.
  • QS Investors sold 462 RAPT Therapeutics shares in Q2 2021, an estimated $86.3K.
  • RAPT Therapeutics made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #826 holding.
  • QS Investors first reported a position in RAPT Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • 109 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.